Vaxcyte Inc. Common Stock vs TTM Technologies Inc. Common Stock — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while TTM Technologies Inc. Common Stock trades at $100.67 (market cap $12.22B). The key difference: TTM Technologies Inc. Common Stock is the larger of the two by market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, TTM Technologies Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and TTM Technologies Inc. Common Stock for 2 Days on average.
| PCVX | TTMI | |
|---|---|---|
Market Cap | $10.51B | $12.22B |
Volume | 2,644,694 | 3,732,329 |
Sector | Health | Technology |
52-Week High | $73.82 | $221.47 |
52-Week Low | $40.32 | $55.69 |
Typical Hold Time | 0 Days | 2 Days |
Enterprise Value | $9.14B | $12.82B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TTMI trades at $116.10, up 5.23% today, but faces a bearish technical signal. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Strong revenue growth is projected, from $2.9B in 2025 to $3.4B in 2026, alongside a rising net profit margin. A significant $1.7B defense backlog and expansion in AI data-center demand support the growth narrative, though the stock's valuation multiples appear elevated.
The outlook is mixed; robust fundamentals and overwhelming analyst buy ratings (85.7%) suggest long-term potential, with a consensus price target of $203.67 implying substantial upside. However, near-term technical weakness and high valuation ratios relative to profitability metrics present risks, requiring careful monitoring of execution against growth expectations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →TTM Technologies manufactures printed circuit boards, radio-frequency components, and electronics assemblies. Its products are used in aerospace, defense, automotive, data center, and communications equipment.
Read more on TTMI →